Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04824092
Title Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (frontMIND)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors MorphoSys AG
Indications

diffuse large B-cell lymphoma

follicular lymphoma

MALT lymphoma

B-cell lymphoma

Therapies

Cyclophosphamide + Doxorubicin + Lenalidomide + Prednisone + Rituximab + Tafasitamab-cxix + Vincristine Sulfate

Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | AUT

Additional content available in CKB BOOST